Corporate News – Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Inc. (SGMT) traded up 2.57 % during the 24‑hour period ending at 06:30 PM Central Europe on Thursday, 22 October 2026. At the close, one share was available on major exchanges for approximately USD 9.85. The company’s current share supply stands at 70.9 million, yielding a market capitalisation of USD 690.7 million. In the past 24 hours, roughly USD 15.8 million of SGMT shares changed hands. Since the close of the previous month, the stock has declined by 9.92 %. The simple moving average over the last 200 trading days sits at USD 7.35. Within the last 52 weeks, the highest price reached USD 11.45 on 10 September 2026, while the lowest price fell to USD 4.50 on 30 March 2026.

Recent Development: Phase 3 AURORA Trial of Denifanstat

Sagimet Biosciences Inc. announced that the first patient has been dosed in its U.S. Phase 3 AURORA trial of the fatty‑acid‑synthase (FASN) inhibitor denifanstat for moderate‑to‑severe acne. The trial, designed to enroll approximately 800 participants, aims to support a potential U.S. New Drug Application (NDA). Topline results are expected in the second half of 2027. Earlier Phase 3 data from the company’s license partner Ascletis in China showed that denifanstat met all primary and secondary endpoints in a 12‑week double‑blind study and was generally well tolerated, with further improvements observed in a 52‑week open‑label extension. The company highlighted that denifanstat offers a novel, once‑daily oral mechanism of action that could address an unmet need among the estimated ten million U.S. patients with moderate‑to‑severe acne. The AURORA study will include a 12‑week double‑blind period followed by a 40‑week open‑label extension to assess long‑term safety. Sagimet remains focused on advancing the registrational programme, with additional data expected to support regulatory submissions in the coming year.

Context from Peer Activity

Other healthcare and industrial stocks have exhibited varied performance over the same 24‑hour window:

  • Dream Finders Homes (DFH) fell 5.94 % to USD 10.01, reflecting a broader pullback in the homebuilding sector amid elevated interest rates. The company’s recent acquisition of Beazer Homes USA, closed on 20 October 2026, is being positioned as a strategic expansion that should generate cost synergies while maintaining an asset‑light model.

  • Abacus Global Management (ABX) rose 1.31 % to USD 8.59, buoyed by a shareholder letter outlining progress across rare‑earth, hydrogen‑fluoride, and bauxite projects. The firm’s emphasis on disciplined development and strategic partnerships aims to secure long‑term value for investors.

  • Gmr (GMRS) slipped 0.76 % to USD 10.37, South Plains (SPFI) dropped 0.87 % to USD 44.07, and Esperion Therapeutics (0ET.F) fell 0.31 % to USD 3.18, all reflecting broader market volatility.

Company Profile

Sagimet Biosciences Inc. is a clinical‑stage biopharmaceutical company headquartered in San Mateo, United States. The company specialises in developing fatty‑acid‑synthase (FASN) inhibitors to treat a range of conditions, including non‑alcoholic steatohepatitis (NASH), acne, and various cancers. Sagimet’s products are aimed at the global market, and its shares trade on Nasdaq following an initial public offering on 13 July 2023. For further information, visit www.sagimet.com .